These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

379 related articles for article (PubMed ID: 19088018)

  • 21. New prognostic and predictive factors in breast cancer.
    Schmidt M; Gehrmann M; Hengstler JG; Koelbl H
    Minerva Ginecol; 2010 Dec; 62(6):599-611. PubMed ID: 21079580
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Interview with private lecturer Dr. med. Nadia Harbeck, Munich. Prognostic markers guide therapy (interview by Jochen Aumiller)].
    Harbeck N
    MMW Fortschr Med; 2003 Jan; 145(3-4):8, 10. PubMed ID: 12619225
    [No Abstract]   [Full Text] [Related]  

  • 23. Pharmacodiagnostics and targeted therapies - a rational approach for individualizing medical anticancer therapy in breast cancer.
    Jørgensen JT; Nielsen KV; Ejlertsen B
    Oncologist; 2007 Apr; 12(4):397-405. PubMed ID: 17470682
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular prognostic factors for breast cancer metastasis and survival.
    Esteva FJ; Sahin AA; Cristofanilli M; Arun B; Hortobagyi GN
    Semin Radiat Oncol; 2002 Oct; 12(4):319-28. PubMed ID: 12382190
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Commercialized multigene predictors of clinical outcome for breast cancer.
    Ross JS; Hatzis C; Symmans WF; Pusztai L; Hortobágyi GN
    Oncologist; 2008 May; 13(5):477-93. PubMed ID: 18515733
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Growth factor signalling in clinical breast cancer and its impact on response to conventional therapies: a review of chemotherapy.
    Barrett-Lee PJ
    Endocr Relat Cancer; 2005 Jul; 12 Suppl 1():S125-33. PubMed ID: 16113089
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Prognostic factors in carcinoma of the breast. Thereupon depends success of the treatment].
    Schneeweiss A; Thomssen Ch; Harbeck N; Bastert G
    MMW Fortschr Med; 2003 Jun; 145(24):34-6, 38. PubMed ID: 12866297
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical use of biomarkers in breast cancer: Updated guidelines from the European Group on Tumor Markers (EGTM).
    Duffy MJ; Harbeck N; Nap M; Molina R; Nicolini A; Senkus E; Cardoso F
    Eur J Cancer; 2017 Apr; 75():284-298. PubMed ID: 28259011
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic factors for breast cancer and their use in the clinical setting.
    Kapoor A; Vogel VG
    Expert Rev Anticancer Ther; 2005 Apr; 5(2):269-81. PubMed ID: 15877524
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pathways to personalized medicine for breast and prostate cancers: emerging diagnostic methods and prognostic biomarkers.
    Watson AP; Egland KA
    S D Med; 2010 Jul; 63(7):247-53. PubMed ID: 20666024
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Quantitative justification of the change from 10% to 30% for human epidermal growth factor receptor 2 scoring in the American Society of Clinical Oncology/College of American Pathologists guidelines: tumor heterogeneity in breast cancer and its implications for tissue microarray based assessment of outcome.
    Moeder CB; Giltnane JM; Harigopal M; Molinaro A; Robinson A; Gelmon K; Huntsman D; Camp RL; Rimm DL; ;
    J Clin Oncol; 2007 Dec; 25(34):5418-25. PubMed ID: 18048824
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of molecular biology on the clinical management of breast cancer.
    Leinster SJ
    Biochem Soc Symp; 1998; 63():185-91. PubMed ID: 9513722
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer.
    Baselga J; Semiglazov V; van Dam P; Manikhas A; Bellet M; Mayordomo J; Campone M; Kubista E; Greil R; Bianchi G; Steinseifer J; Molloy B; Tokaji E; Gardner H; Phillips P; Stumm M; Lane HA; Dixon JM; Jonat W; Rugo HS
    J Clin Oncol; 2009 Jun; 27(16):2630-7. PubMed ID: 19380449
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A genetic signature can predict prognosis and response to therapy in breast cancer: Oncotype DX.
    Kaklamani V
    Expert Rev Mol Diagn; 2006 Nov; 6(6):803-9. PubMed ID: 17140367
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Predictive factors of hormonal therapy in breast cancer].
    Iwase H
    Nihon Rinsho; 2006 Mar; 64(3):555-60. PubMed ID: 16529049
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Progression of breast tumors is accompanied by a decrease in expression of the Rho guanine exchange factor Tiam1.
    Stebel A; Brachetti C; Kunkel M; Schmidt M; Fritz G
    Oncol Rep; 2009 Jan; 21(1):217-22. PubMed ID: 19082465
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Can we replace the microscope with microarrays for diagnosis, prognosis and treatment of early breast cancer?
    Glück S; Yip AY; Ng EL
    Expert Opin Ther Targets; 2012 Mar; 16 Suppl 1():S17-22. PubMed ID: 22316427
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Integrating molecular profiling, histological type and other variables: defining the fingerprint of responsiveness to treatment.
    Viale G
    Breast; 2009 Oct; 18 Suppl 3():S32-6. PubMed ID: 19914539
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The role of topoisomerase IIalpha and HER-2 in predicting sensitivity to anthracyclines in breast cancer patients.
    Oakman C; Moretti E; Galardi F; Santarpia L; Di Leo A
    Cancer Treat Rev; 2009 Dec; 35(8):662-7. PubMed ID: 19758759
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Predicting response to therapy in breast cancer].
    Strunz K; Deissler H; Kreienberg R; Sauer G
    Gynakol Geburtshilfliche Rundsch; 2008; 48(3):113-7. PubMed ID: 18566527
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.